| Title |
Evidence-Based Management of Statin Myopathy
|
|---|---|
| Published in |
Current Atherosclerosis Reports, July 2010
|
| DOI | 10.1007/s11883-010-0120-9 |
| Pubmed ID | |
| Authors |
Charles R. Harper, Terry A. Jacobson |
| Abstract |
Statin-associated muscle symptoms are a relatively common condition that may affect 10% to 15% of statin users. Statin myopathy includes a wide spectrum of clinical conditions, ranging from mild myalgia to rhabdomyolysis. The etiology of myopathy is multifactorial. Recent studies suggest that statins may cause myopathy by depleting isoprenoids and interfering with intracellular calcium signaling. Certain patient and drug characteristics increase risk for statin myopathy, including higher statin doses, statin cytochrome metabolism, and polypharmacy. Genetic risk factors have been identified, including a single nucleotide polymorphism of SLCO1B1. Coenzyme Q10 and vitamin D have been used to prevent and treat statin myopathy; however, clinical trial evidence demonstrating their efficacy is limited. Statin-intolerant patients may be successfully treated with either low-dose statins, alternate-day dosing, or using twice-weekly dosing with longer half-life statins. An algorithm is presented to assist the clinician in managing myopathy in patients with dyslipidemia. |
Mendeley readers
The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Canada | 2 | 2% |
| Colombia | 1 | <1% |
| Australia | 1 | <1% |
| Brazil | 1 | <1% |
| Denmark | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 98 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 14% |
| Researcher | 14 | 13% |
| Student > Master | 13 | 12% |
| Student > Bachelor | 11 | 10% |
| Student > Postgraduate | 10 | 9% |
| Other | 35 | 33% |
| Unknown | 9 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 51 | 48% |
| Agricultural and Biological Sciences | 12 | 11% |
| Biochemistry, Genetics and Molecular Biology | 7 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 6% |
| Neuroscience | 4 | 4% |
| Other | 11 | 10% |
| Unknown | 16 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 October 2015.
All research outputs
#4,695,037
of 22,782,096 outputs
Outputs from Current Atherosclerosis Reports
#245
of 763 outputs
Outputs of similar age
#19,620
of 94,847 outputs
Outputs of similar age from Current Atherosclerosis Reports
#4
of 8 outputs
Altmetric has tracked 22,782,096 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 763 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.7. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 94,847 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.